scholarly journals The role of vitamin D and SLCO1B1 gene polymorphism in statin-associated myalgias

2010 ◽  
Vol 2 (2) ◽  
pp. 77-84 ◽  
Author(s):  
Randy Linde ◽  
Lihong Peng ◽  
Manisha Desai ◽  
David Feldman
Keyword(s):  
Vitamin D ◽  
Gene Polymorphism ◽  
Slco1b1 Gene

95-P: Role of vitamin D receptor gene polymorphism in tuberculosis

2007 ◽  
Vol 68 (1) ◽  
pp. S62
Author(s):  
Angel R. Villasmil ◽  
Mercedes T. Fernandez-Mestre ◽  
Violeta Ogando ◽  
Zulay E. Layrisse
Keyword(s):  
Vitamin D ◽  
Gene Polymorphism ◽  
Vitamin D Receptor ◽  
Receptor Gene ◽  
Vitamin D Receptor Gene ◽  
Receptor Gene Polymorphism

scholarly journals The Role of Apa-I Vitamin D Receptor Gene Polymorphism in Type 2 Diabetes Mellitus

2021 ◽  
Vol 9 (A) ◽  
pp. 129-133
Author(s):  
Mutiara Indah Sari ◽  
Rusdiana Rusdiana ◽  
Milahayati Daulay
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Vitamin D ◽  
Gene Polymorphism ◽  
Vitamin D Receptor ◽  
Receptor Gene ◽  
Vitamin D Receptor Gene ◽  
Receptor Gene Polymorphism

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic metabolic syndrome caused by insulin secretion abnormalities, insulin action, or both. Gene polymorphism is a risk factor of T2DM. AIM: This study aims to see the role of Apa-I Vitamin D receptor gene polymorphism on T2DM. METHODS: This study was an analytic observational with a case–control approach, consisting of 70 T2DM patients and 70 healthy subjects as a control. Genotyping of the Apa-I Vitamin D receptor gene polymorphism was performed using the polymerase chain reactions-restriction fragment length polymorphisms method. The role of the Apa-I Vitamin D receptor gene polymorphism and the risk of T2DM were analyzed using the Chi-square test. RESULTS: The results showed that there was a significant association between codominant (TT genotype); dominant; recessive models of the Apa-I Vitamin D receptor gene polymorphism with the risk of T2DM (p < 0.05; odds ratio [OR] = 0.204, 95% confidence interval [CI] = 0.063–0.662; OR = 0.337, 95% CI = 0.113–1.004; OR = 0.367, 95% CI = 0.180–0.747, respectively), but not in codominant (GT genotype) and over-dominant models (p > 0.05). CONCLUSION: This study shows a role of the codominant (TT genotype); dominant; recessive models of the Apa-I Vitamin D receptor gene polymorphism on T2DM, but not in codominant (GT genotype) and over-dominant models.

The role of vitamin D in metabolic and reproductive disturbances of polycystic ovary syndrome: A narrative mini-review

2020 ◽  
pp. 1-8
Author(s):  
Daniela Menichini ◽  
Gianpiero Forte ◽  
Beatrice Orrù ◽  
Giuseppe Gullo ◽  
Vittorio Unfer ◽  
...  
Keyword(s):  
Vitamin D ◽  
Polycystic Ovary Syndrome ◽  
Embryo Quality ◽  
Polycystic Ovary ◽  
Vitamin D Supplementation ◽  
Endometrial Receptivity ◽  
Metabolic Disturbances ◽  
Ovary Syndrome ◽  
Beneficial Role

Abstract. Vitamin D is a secosteroid hormone that plays a pivotal role in several metabolic and reproductive pathways in humans. Increasing evidence supports the role of vitamin D deficiency in metabolic disturbances and infertility in women with polycystic ovary syndrome (PCOS). Indeed, supplementation with vitamin D seems to have a beneficial role on insulin resistance and endometrial receptivity. On the other hand, exceedingly high levels of vitamin D appear to play a detrimental role on oocytes development and embryo quality. In the current review, we summarize the available evidence about the topic, aiming to suggest the best supplementation strategy in women with PCOS or, more generally, in those with metabolic disturbances and infertility. Based on the retrieved data, vitamin D seems to have a beneficial role on IR, insulin sensitivity and endometrial receptivity, but high levels and incorrect timing of administration seem to have a detrimental role on oocytes development and embryo quality. Therefore, we encourage a low dose supplementation (400–800 IU/day) particularly in vitamin D deficient women that present metabolic disturbances like PCOS. As far as the reproductive health, we advise vitamin D supplementation in selected populations, only during specific moments of the ovarian cycle, to support the luteal phase. However, ambiguities about dosage and timing of the supplementation still emerge from the clinical studies published to date and further studies are required.

Sign in / Sign up

Export Citation Format

Share Document